Comparison of the Incidence of Dyskinesia in Parkinson's Disease Who Were Treated With Amantadine or Dopamine Agonist
- Conditions
- Parkinson's Disease
- Registration Number
- NCT01338662
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
The purpose of this study is to compare the onset time and severity of dyskinesia in amantadine or Dopamine agonist initial treated groups in Parkinson's disease.
- Detailed Description
1. Dopamine agonist can delay the risk of dyskinesia by initiating treatment rather than levodopa. Amantadine is typical antidyskinetic drug. There is no data about comparison of risk of dyskinesia in amantadine and dopamine agonist by initiating treatment.
2. Prospective , randomized, open label study compare the onset time and severity of dyskinesia between groups randomized assigned order of amantadine and dopamine agonist
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 500
- 30<age<60
- IPD
- H & Y<3
- previous dopaminergic medication history
- dyskinesia
- Parkinson plus
- clinically significant or unstable medical or surgical condition
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method dyskinesia onset up to 10 years from the start of durg (Amantadine or dopaimine agonsit) observe duration of onset of dyskinesia from initial treatment observe until 10 years
- Secondary Outcome Measures
Name Time Method UPDRS, severity of dyskinesia between groups observe duration of onset of dyskinesia from initial treatment observe duration of onset of dyskinesia from initial treatment observe until 10 years compare the UPDRS and severity of dyskinesia between groups
Trial Locations
- Locations (1)
Beom S Jeon
🇰🇷Seoul, Korea, Republic of